Keywords: Boehringer Ingelheim, Spiriva, Pfizer, GlaxoSmithKline, Advair, Decision Resources, COPD
Increased use of Spiriva will be driven by greater first-line maintenance use
Article | 08 December 2010
Privately-held German drug major Boehringer Ingelheim and pharma behemoth Pfizer's (NYSE: PFE) Spiriva (tiotropium will most likely strengthen its position ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
